{
  "docId": "019de073-6334-73fa-be75-ee71680dfe14",
  "docSlug": "515ba39d2bbce909d673d084274607f0",
  "documentTitle": "Perella Weinberg Partners | Investment Banking Pitch Book | 10 slides",
  "authorId": "perella-weinberg-partners",
  "authorName": "Perella Weinberg Partners",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 3,
  "pageCount": 10,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "agenda",
  "function": "frame_problem",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-6334-73fa-be75-ee71680dfe14/3",
  "deckHref": "/decks/019de073-6334-73fa-be75-ee71680dfe14",
  "deckJsonHref": "/decks/019de073-6334-73fa-be75-ee71680dfe14.json",
  "deckAnchorHref": "/decks/019de073-6334-73fa-be75-ee71680dfe14#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.37,
        "x": 0.315,
        "y": 0.01
      },
      "kind": "callout",
      "text": "Preliminary",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8eadf008-e5d9-4361-9f19-f1b0a8ef3f47",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.91,
        "x": 0.045,
        "y": 0.0018
      },
      "kind": "list",
      "text": "In general, provide context to the process of developing and updating the long-range plan. How is each product line forecasted and validated internally?\nProvide commentary on the expected erosion of SmartFresh Apple and the factors driving customer retention versus cheaper generics in the market today\nDiscuss risks related to competition within SmartFresh Diversification – should we expect similar erosion if and when generics enter the market?\n2026E represents a critical year of growth – please provide commentary on the expected new major product launches of Harvista, Novel Antimicrobial and Novozymes Biologics\nWhat is your confidence level in and key risks to achieving the product launch schedule laid out in the plan?\nPlease discuss gross margin evolution as it relates to continued diversification into lower margin products – are there certain products of focus to maintain a higher gross margin?\nProvide color on operating leverage expected from R&D, S&M and G&A over the forecast period",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b06027c-924d-4a39-a6ed-231ee9fdbb5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.22,
        "x": 0.045,
        "y": 0.08
      },
      "kind": "title",
      "text": "Key Questions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "217cfaf2-ebdc-4f99-a4bf-f9d555ffb267",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 3,
      "from": 3,
      "beatId": "06fc85b2-cd68-4a65-a152-0650b05f0eb5",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "The agenda slide highlights key questions, indicating areas of focus.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}